First Report of an Extensively Drug-Resistant VIM-2 Metallo-β-Lactamase-Producing Brevundimonas diminuta Clinical Isolate

Almuzara, Marisa; Barberis, Claudia; Rodríguez, Carlos Hernán; Famiglietti, Ángela; Ramírez, María Soledad; Vay, Carlos

doi:10.1128/jcm.00924-12

Cited by 18 publications

(22 citation statements)

References 14 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[12][13][14] This case is the first reported peritonitis case in a peritoneal dialysis patient due to B. diminuta. Our patient has not any malignity and did not use any immunosupressed agent.…”

mentioning

confidence: 78%

See 1 more Smart Citation

A Rare Peritonitis Cause in a Peritoneal Dialysis Patient: Brevundimonas diminuta: Case Report

Altunören¹,

Güngör²,

Güler³

et al. 2015

Turkiye Klinikleri J Nephrol

View full text Add to dashboard Cite

mentioning

confidence: 78%

“…This bacteria are usually susceptible to aminoglycoside, piperacillin-tazobactam and imipenem. [9][10][11][12][13][14] The true mechanisms of the resistance to various antibiotics are unclear. Carbapenem together with piperacillin/tazobactam may be the most reliable antibiotic for treating bacteriemia caused by Brevundimonas species.…”

mentioning

confidence: 99%

A Rare Peritonitis Cause in a Peritoneal Dialysis Patient: Brevundimonas diminuta: Case Report

Altunören¹,

Güngör²,

Güler³

et al. 2015

Turkiye Klinikleri J Nephrol

View full text Add to dashboard Cite

“…Some published studies have shown that; B. diminuta has variable resistance against some antimicrobial agents such as; azteronam, ciprofloxacin, ceftazidime (Gilad et al, 2000, Chi et al, 2004Han and Andrade, 2005;Choi et al, 2006;Almuzara et al, 2012). Susceptibility to the cefepime as 4 th generation of cephalosporins was reported in one case (Choi et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

“…In current study, azythromycin (exception one B. subvibrioides), gentamycin exhibited high affect in antibiogram process and could be considered as a treatment option. Detection of responsible genes or other mechanisms in our B. diminuta isolates need to more study (Almuzara et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

First report of isolation and identification of Brevundimonase (Pseudomonas) diminuta from collected nasopharyngeal specimens in suspected patients to pertussis

Mirzaei¹,

Torkaman²,

Babaei³

et al. 2014

Afr. J. Microbiol. Res.

View full text Add to dashboard Cite

Brevundimonase diminuta as an opportunistic environmental bacterium, due to the increase in isolation rate from clinical specimens and its antibiotic resistance is considered as a new threat to human health care. After performing conventional phenotypic methods and molecular approaches, antibiotics resistance pattern on the identified Brevundimonase isolates was performed as minimum bactericidal concentration by disk diffusion method. Out of 1084 nasopharyngeal specimens, 2/1084 (%0.18) Brevundimonase diminuta, and 1/1084 (%0.09) Brevundimonase subvibrioides were isolated. Evaluation of the resistance pattern from isolated Brevundimonase strains indicated that: levofloxacin, ciprofloxacin, ampicillin, amikacin (Excluding B. subvibrioides), chloroamphenicol and ceftazidime had poor susceptibility results. Also azythromycin, gentamycin, sulfamethoxazole/trimethoprim (Excluding B. subvibrioides), ciprofloxacin, kanamycin showed good susceptibility results against Brevundimonase isolated strains. In conclusion, Although, Brevundimonase diminuta rarely has been isolated from other clinical specimens, but, due to reports of resistance to some of antimicrobial agents in this genus all laboratories should be equipped for the identification and evaluation of susceptibility patterns of this species. It is first the report of isolated Brevundimonase diminuta from nasopharyngeal specimen from suspected patients to pertussis in Iran.

show abstract

Identification and Validation Novel of VIM‐2 Metallo‐β‐lactamase Tripeptide Inhibitors

Xiao

Fang

Shi

et al. 2015

Molecular Informatics

View full text Add to dashboard Cite

The development of novel inhibitors against metallo-β-lactamase is essential to remedy metallo-β-lactamase mediated bacterial resistance. A recently emerged metallo-β-lactamase, VIM-2, has demonstrated resistance to existing β-lactamase inhibitors in the clinic. In this study, a hybrid virtual screening protocol that combines pharmacophore modeling, molecular docking, and calculation of binding free energy was employed to screen an internal tripeptide database for novel inhibitors against VIM-2. This resulted in four tripeptides (WWC, WCW, MCW, YCW) as potential inhibitors, and their effects on VIM-2 metallo-β-lactamase were subsequently tested in vitro. Significantly, two peptides (MCW, YCW) exhibited potent inhibitory activities with IC50 values of 18.15 µM and 52.9 µM, respectively. To our knowledge, this is the first study that employed the hybrid virtual screening of combinational peptide database and discovered potent peptide inhibitors of VIM-2 metallo-β-lactamase.

show abstract

First Report of an Extensively Drug-Resistant VIM-2 Metallo-β-Lactamase-Producing Brevundimonas diminuta Clinical Isolate

Cited by 18 publications

References 14 publications

A Rare Peritonitis Cause in a Peritoneal Dialysis Patient: Brevundimonas diminuta: Case Report

A Rare Peritonitis Cause in a Peritoneal Dialysis Patient: Brevundimonas diminuta: Case Report

First report of isolation and identification of Brevundimonase (Pseudomonas) diminuta from collected nasopharyngeal specimens in suspected patients to pertussis

Identification and Validation Novel of VIM‐2 Metallo‐β‐lactamase Tripeptide Inhibitors

Contact Info

Product

Resources

About